Cyclooxygenase-2 (COX-2) inhibitors have long been employed to modulate inflammatory responses in a range of conditions, from arthritis to malignancies. In recent years, the convergence of ...
Cholangiocarcinoma is a rare but highly malignant primary hepatobiliary cancer with a high rate of mortality. Early diagnosis is difficult and current therapies are ineffective for the advanced ...
Over the past five years, selective cyclooxygenase-2 inhibitors (coxibs) have accounted for a growing proportion of prescriptions for nonsteroidal antiinflammatory drugs (NSAIDs). To control these ...
The results of the clinical trial by Smith et al 1 confirm that celecoxib does seem to inhibit rising PSA levels in men who have undergone treatment for prostate cancer. Questions still remain as to ...
To the Editor: The review article by FitzGerald and Patrono (Aug. 9 issue) 1 on the coxibs, selective inhibitors of cyclooxygenase-2 (COX-2), included a table listing pharmacokinetic and metabolic ...
Phase I Trial of Gefitinib in Combination With Radiation or Chemoradiation for Patients With Locally Advanced Squamous Cell Head and Neck Cancer COX-2 methylation status was initially assessed by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results